BoMed Inc. is R&D company, with expertise in TEB (Thoracic Electrical Bioimpedance) Technology (sometimes called IPG - Impedance Cardiography) and in hemodynamics and hemodynamic management.

BoMed has developed a series of TEB products  - TEBCO, EXT-TEBCO and TEBCO-W - both for the OEM market and for use in its own systems.

Our proprietary TEB  Technology and the Hemodynamic Management methodology are implemented in BoMed's main product - the HOTMAN System.

HOTMAN System (Hemodynamic & Oxygen Transport Management System), with its hemodynamic assessment, monitoring, management and modeling capability replaces current trial-and-error hemodynamic management methodology with a straight-line, normohemodynamic goal-oriented therapy. As a result, it shortens the duration of therapy and dramatically improves outcomes, especially in treatment of hypertension and CHF (Congestive Heart Failure). It significantly reduces the number of expensive cardio- and vasoactive drugs needed to treat hemodynamic disorders. With all these factors combined, it profoundly reduces the cardiovascular health care cost and may improve the quality of life in aging population.

BoMed is close to completing the development of the next generation product - the wireless, Cloud-based version of the HOTMAN System with patient's hemodynamic data processing and storage on the Cloud and data display capability on a broad range of devices from a smart phone, tablet, all the way up to a PC. This product will enable instant data sharing between the patient, his physician and medical institution, and opens new consumer market. BoMed is seeking strategic partner to manufacture and market this product.

BoMed also sells two medical and biomedical engineering textbooks: "Systemic Hemodynamics and Hemodynamic Management" and "Biomechanics of the Cardiovascular System"

HOTMAN Systems and all of their modules have the FDA 510(k) marketing clearances.